1-20 of 33
Charles Erlichman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 4631: Pharmacokinetics and in vivo metabolism of Z-endoxifen: Results from two phase I studies in women with ER+ breast cancer, gynecologic malignancies and desmoids

Joel M. Reid, Matthew P. Goetz, Shivaani Kumar, Renee M. McGovern, Sarah A. Buhrow, Stephanie L. Safgren, Vera J. Suman, Travis J. Docktor, Charles Erlichman, Howard Streicher, James H. Doroshow, Jerry Collins, Matthew M. Ames
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 4631.
https://doi.org/10.1158/1538-7445.AM2014-4631
Published: 01 October 2014
View article titled, Abstract 4631: Pharmacokinetics and in vivo metabolism of Z-endoxifen: Results from two phase I studies in women with ER+ breast cancer, gynecologic malignancies and desmoids
Journal Articles

Poly(ADP-Ribose) Polymerase Inhibition Synergizes with 5-Fluorodeoxyuridine but not 5-Fluorouracil in Ovarian Cancer Cells

Amelia M. Huehls, Jill M. Wagner, Catherine J. Huntoon, Liyi Geng, Charles Erlichman, Anand G. Patel, Scott H. Kaufmann, Larry M. Karnitz
Journal: Cancer Research
Cancer Res (2011) 71 (14): 4944–4954.
https://doi.org/10.1158/0008-5472.CAN-11-0814
Published: 14 July 2011
View article titled, Poly(ADP-Ribose) Polymerase Inhibition Synergizes with 5-Fluorodeoxyuridine but not 5-Fluorouracil in Ovarian Cancer Cells
Open the PDF for Poly(ADP-Ribose) Polymerase Inhibition Synergizes with 5-Fluorodeoxyuridine but not 5-Fluorouracil in Ovarian Cancer Cells in another window
Includes: Supplementary data
Journal Articles

Abstract 4712: Evidence of clinical efficacy of the combination of flavopiridol (Alvocidib) and cisplatin in platin-resistant ovarian and primary peritoneal carcinoma: Phase 2 trial MC0261

Keith Christopher Bible, Prema P. Peethambaram, Ann L. Oberg, William J. Maples, David L. Groteluschen, Matthew Boente, Jill K. Burton, Leigh C. Gomez-Dahl, Jennifer D. Tibodeau, Crescent R. Isham, Andrea K. Kukla, Kalli J. Voll, Alexander D. Colevas, John Wright, L Austin Doyle, Charles Erlichman, Mayo Phase Consortium
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 4712.
https://doi.org/10.1158/1538-7445.AM2011-4712
Published: 15 April 2011
View article titled, Abstract 4712: Evidence of clinical efficacy of the combination of flavopiridol (Alvocidib) and cisplatin in platin-resistant ovarian and primary peritoneal carcinoma: Phase 2 trial MC0261
Journal Articles

Abstract 1301: Investigation of a potential pharmacokinetic interaction between ABT-888 and topotecan in a phase I trial

Olumide Kayode, Joel M. Reid, Danel V. Satele, Hui Tang, Paul Haluska, Prema P. Peethambaram, Matthew M. Ames, Alice Chen, Scott H. Kaufmann, Donald W. Northfelt, Charles Erlichman, Michael E. Menefee
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 1301.
https://doi.org/10.1158/1538-7445.AM2011-1301
Published: 15 April 2011
View article titled, Abstract 1301: Investigation of a potential pharmacokinetic interaction between ABT-888 and topotecan in a phase I trial
Journal Articles

Insulin Receptor A and IGF-IR in AML – Response

Andrea E. Wahner Hendrickson, Paul Haluska, Charles Erlichman, Marco Gottardis, Joan E. Carboni, Judith E. Karp, Scott H. Kaufmann
Journal: Cancer Research
Cancer Res (2010) 70 (17): 7010.
https://doi.org/10.1158/0008-5472.CAN-10-1920
Published: 31 August 2010
View article titled, Insulin Receptor A and IGF-IR in AML – Response
Open the PDF for Insulin Receptor A and IGF-IR in AML – Response in another window
Journal Articles

Abstract 1807: Phase I trial of the combined targeting of the Hedgehog (GDC-0449) and EGFR pathways (erlotinib) in pancreatic cancer

Charles Erlichman, Martin Fernandez-Zapico, Mitesh Borad, Julian Molina, Axel Grothey, Henry Pitot, Aminah Jatoi, Donald Northfelt, Robert McWilliams, Scott Okuno, Paul Haluska
Journal: Cancer Research
Cancer Res (2010) 70 (8_Supplement): 1807.
https://doi.org/10.1158/1538-7445.AM10-1807
Published: 15 April 2010
View article titled, Abstract 1807: Phase I trial of the combined targeting of the Hedgehog (GDC-0449) and EGFR pathways (erlotinib) in pancreatic cancer
Journal Articles

Expression of Insulin Receptor Isoform A and Insulin-like Growth Factor-1 Receptor in Human Acute Myelogenous Leukemia: Effect of the Dual-Receptor Inhibitor BMS-536924 In vitro

Andrea E. Wahner Hendrickson, Paul Haluska, Paula A. Schneider, David A. Loegering, Kevin L. Peterson, Ricardo Attar, B. Douglas Smith, Charles Erlichman, Marco Gottardis, Judith E. Karp, Joan M. Carboni, Scott H. Kaufmann
Journal: Cancer Research
Cancer Res (2009) 69 (19): 7635–7643.
https://doi.org/10.1158/0008-5472.CAN-09-0511
Published: 01 October 2009
View article titled, Expression of Insulin Receptor Isoform A and Insulin-like Growth Factor-1 Receptor in Human Acute Myelogenous Leukemia: Effect of the Dual-Receptor Inhibitor BMS-536924 <em>In vitro</em>
Open the PDF for Expression of Insulin Receptor Isoform A and Insulin-like Growth Factor-1 Receptor in Human Acute Myelogenous Leukemia: Effect of the Dual-Receptor Inhibitor BMS-536924 <em>In vitro</em> in another window
Includes: Supplementary data
Journal Articles

Abstract #3600: Phase I pharmacokinetics and pharmacodynamics of the aminoflavone prodrug AFP464

Joel Reid, Renee McGovern, Kathryn Reinicke, Mary Kuffel, Matthew Ames, Yingwei Qi, Charles Erlichman, Matthew Goetz
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): 3600.
Published: 01 May 2009
View article titled, Abstract #3600: Phase I pharmacokinetics and pharmacodynamics of the aminoflavone prodrug AFP464
Journal Articles

Abstract #3591: Final analysis of MC027C: a phase I trial of CCI-779 and EKB-569 in patients with advanced solid tumors

Alan Bryce, Jann Sarkaria, Joel Reid, Ravi Rao, Yingwei Qi, Rui Qin, C James, Robert Jenkins, Charles Erlichman
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): 3591.
Published: 01 May 2009
View article titled, Abstract #3591: Final analysis of MC027C: a phase I trial of CCI-779 and EKB-569 in patients with advanced solid tumors
Journal Articles

Abstract #4665: A phase I dose escalation study of the PKC inhibitor Aurothiomalate (ATM) in patients with advanced NSCLC and ovarian cancer, safety and anti-tumor activity

Julian Molina, Alan Fields, Yingwei Qi, Rui qin, Sara Felten, Alex Adjei, Gretchen Batzel, Charles Erlichman
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): 4665.
Published: 01 May 2009
View article titled, Abstract #4665: A phase I dose escalation study of the PKC inhibitor Aurothiomalate (ATM) in patients with advanced NSCLC and ovarian cancer, safety and anti-tumor activity
Journal Articles

Abstract #3602: Ongoing phase 1 study of a novel PARP inhibitor, ABT-888 in combination with temozolamide; Pharmacokinetics, safety and anti-tumor activity

Julian Molina, Charles Erlichman, Donald Northfelt, Janeth Lensing, Vincent Giranda
Journal: Cancer Research
Cancer Res (2009) 69 (9_Supplement): 3602.
Published: 01 May 2009
View article titled, Abstract #3602: Ongoing phase 1 study of a novel PARP inhibitor, ABT-888 in combination with temozolamide; Pharmacokinetics, safety and anti-tumor activity
Journal Articles

P-Glycoprotein–Mediated Resistance to Hsp90-Directed Therapy Is Eclipsed by the Heat Shock Response

Andrea K. McCollum, Cynthia J. TenEyck, Bridget Stensgard, Bruce W. Morlan, Karla V. Ballman, Robert B. Jenkins, David O. Toft, Charles Erlichman
Journal: Cancer Research
Cancer Res (2008) 68 (18): 7419–7427.
https://doi.org/10.1158/0008-5472.CAN-07-5175
Published: 14 September 2008
View article titled, P-Glycoprotein–Mediated Resistance to Hsp90-Directed Therapy Is Eclipsed by the Heat Shock Response
Open the PDF for P-Glycoprotein–Mediated Resistance to Hsp90-Directed Therapy Is Eclipsed by the Heat Shock Response in another window
Includes: Supplementary data
Journal Articles

Cisplatin abrogates the geldanamycin-induced heat shock response

Charles Erlichman, Andrea McCollum, Kara Lukasiewicz, Cynthia TenEyck, Wilma Lingle, David Toft
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): 1464.
Published: 01 May 2008
View article titled, Cisplatin abrogates the geldanamycin-induced heat shock response
Journal Articles

GLI1 integrates EGF into the Hedgehog signaling network in pancreatic cancer cells

Luciana Almada, Jing-Jing Han, L Pena-Sanchez, Charles Erlichman, Martin Fernandez-Zapico
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): 864.
Published: 01 May 2008
View article titled, GLI1 integrates EGF into the Hedgehog signaling network in pancreatic cancer cells
Journal Articles

Hedgehog-independent activation of GLI transcriptional activity

Luciana Almada, Jennifer Heim, Jing-Jing Han, Charles Erlichman, Martin Fernandez-Zapico
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): 863.
Published: 01 May 2008
View article titled, Hedgehog-independent activation of GLI transcriptional activity
Journal Articles

Co-inhibition of the IGF-1R and HER family of receptors stimulates synergistic cell death in human ovarian cancer cells

Paul Haluska, Chunrong Yu, Joan Carboni, Diane Soeffker, Tai Wong, Mark Saulnier, Ricardo Attar, Mark Wittman, Scott Kaufmann, Marco Gottardis, Charles Erlichman
Journal: Cancer Research
Cancer Res (2007) 67 (9_Supplement): 2374.
Published: 01 May 2007
View article titled, Co-inhibition of the IGF-1R and HER family of receptors stimulates synergistic cell death in human ovarian cancer cells
Journal Articles

Up-regulation of Heat Shock Protein 27 Induces Resistance to 17-Allylamino-Demethoxygeldanamycin through a Glutathione-Mediated Mechanism

Andrea K. McCollum, Cynthia J. TenEyck, Brian M. Sauer, David O. Toft, Charles Erlichman
Journal: Cancer Research
Cancer Res (2006) 66 (22): 10967–10975.
https://doi.org/10.1158/0008-5472.CAN-06-1629
Published: 15 November 2006
View article titled, Up-regulation of Heat Shock Protein 27 Induces Resistance to 17-Allylamino-Demethoxygeldanamycin through a Glutathione-Mediated Mechanism
Open the PDF for Up-regulation of Heat Shock Protein 27 Induces Resistance to 17-Allylamino-Demethoxygeldanamycin through a Glutathione-Mediated Mechanism in another window
Journal Articles

Phase I study of CNF1010 (lipid formulation of 17-(allylamino)-17-demethoxygeldanamycin: 17-AAG) in patients with advanced solid tumors

David Mendelson, M. Wasif Saif, Charles Erlichman, Tomislav Dragovich, Michael Gordon, C. D. Toft, Gregg Timony, Francis Burrows, Claire Padgett, Robert L. De Jager, Daniel Von Hoff
Journal: Cancer Research
Cancer Res (2006) 66 (8_Supplement): 683.
Published: 15 April 2006
View article titled, Phase I study of CNF1010 (lipid formulation of 17-(allylamino)-17-demethoxygeldanamycin: 17-AAG) in patients with advanced solid tumors
Journal Articles

A limited sample model for 17-(Allylamino)-17-demethoxygeldanamycin and its active metabolite 17-(amino)-17-demethoxygeldanomycin

Alfred F. Furth, Sumithra J. Mandrekar, Andrea Rau, Joel M. Reid, Angelina Tan, Sara J. Felten, Charles Erlichman, Matthew M. Ames, Alex A. Adjei
Journal: Cancer Research
Cancer Res (2006) 66 (8_Supplement): 737.
Published: 15 April 2006
View article titled, A limited sample model for 17-(Allylamino)-17-demethoxygeldanamycin and its active metabolite 17-(amino)-17-demethoxygeldanomycin
Journal Articles

In vitro and In vivo Antitumor Effects of the Dual Insulin-Like Growth Factor-I/Insulin Receptor Inhibitor, BMS-554417

Paul Haluska, Joan M. Carboni, David A. Loegering, Francis Y. Lee, Mark Wittman, Mark G. Saulnier, David B. Frennesson, Kimberly R. Kalli, Cheryl A. Conover, Ricardo M. Attar, Scott H. Kaufmann, Marco Gottardis, Charles Erlichman
Journal: Cancer Research
Cancer Res (2006) 66 (1): 362–371.
https://doi.org/10.1158/0008-5472.CAN-05-1107
Published: 05 January 2006
View article titled, <em>In vitro</em> and <em>In vivo</em> Antitumor Effects of the Dual Insulin-Like Growth Factor-I/Insulin Receptor Inhibitor, BMS-554417
Open the PDF for <em>In vitro</em> and <em>In vivo</em> Antitumor Effects of the Dual Insulin-Like Growth Factor-I/Insulin Receptor Inhibitor, BMS-554417 in another window